Efficacy and safety of Frexalimab in participants with relapsing multiple sclerosis: 3-year results from the phase 2 open-label extension (EAN 2026) - Jun 12, 2026 - Abstract #EPO-0785; Pres time: Jun 29, 2026; 01:15 PM - 01:20 PM; Location: B5; P2 | "Frexalimab continues to exert sustained reduction in disease activity with favourable safety in pwRMS over 3 years, supporting its further development in phase-3 trials for RMS (FREXALT) and non-relapsing secondary progressive MS (FREVIVA) as a potential high-efficacy, non-lymphocyte-depleting therapy."
Clinical • P2 data • CNS Disorders • Multiple Sclerosis • CD40LG
|
|
P. Vermersch 1; S. Krieger 2; H. Wiendl 3; C. Granziera 4; Y. Mao-Draayer 5; G. Cutter 6; O. Kalbus 7; I. Staikov 8; M. Dufek 9; X. Montalban 10; S. Saubadu 11; X. Luo 12; S. Patel 12; B. Djukic 13; P. Truffinet 11; E. Wallstroem 13; G. Giovannoni 14; on behalf of Frexalimab Phase 2 Trial Group
|